Recent evidence has strengthened its role as an emerging biomarker in breast cancer, particularly in TNBC, where AR expression contributes to a distinct molecular phenotype known as the luminal androgen receptor (LAR) subtype [110]. This evidence concerns the gene AR and breast cancer.